Anti-pottery antibody and its application (anti-pottery antibody)

摘要

1. Requirement 1: A separate antibody or part of its antigen that specifically binds to human protein Tau and is identified in its residues 111-125Q Ibid., No. 1.Requirement 2: Antibody separated from Requirement 1,One or more groups consisting of one or more complementary decision regions, including: (a) a heavy chain CDR with at least 90% sequence characteristicsThe amino acid sequence of Chemical Abstracts No. 22 or the amino acid sequence of Chemical Abstracts No. 22 can replace the amino acid sequence of two amino acids at most; (b) A heavy chain CDR2 containing:The amino acid sequence of Chemical Abstracts No. 23 is less than 90%, or the amino acid sequence of Chemical Abstracts No. 23 has the sequence number of two amino acid substitutes 23.(c) A heavy-chain CDR3 with at least 90% sequence characteristics of the SEQID 24 amino acid sequence, or at most two amino acid substitutes:Amino acid sequence of CAS No. 24; (d) A light chain CDR1, which has at least 90% sequence characteristics consistent with any CAS No. 26 and 42 amino acid sequence, orThere are as many as two amino acid substitutes in any of the amino acid sequences of CAS No. 26 and 42; (e) a light chain CDR2, which has at least 90% safety characteristics.Consistent with the amino acid sequence of any Class 27 Chemical Abstracts Society number,Noting that there are at most two amino acid substitutes for amino acid sequences in general comments 43 and 50, or in any general comment 27,(f) A light chain CDR3 containing at least 90% of the sequence characteristics associated with the sequence of any amino acid sequence numbered 28 and 44 of the Chemical Abstracts Society.According to articles 46 and 51 of the Chemical Weapons Convention, or in any amino acid sequence No. 28, 44, 46 and 51 of the Chemical Abstracts Society, there are up to two amino acid substitutes.Claim No. 191: A pharmaceutical component comprising antibodies separated from Claims No. 1 to 190 and an acceptable pharmaceutical vehicle.Claim 193: A single polynucleoside sequence consisting of nucleoside sequences that encodes antibodies separated from any claim 1 to 190.Claim 197: A Hibridoma cell phone that generates antibody clones of 17G2.A1, 19F7.C9 or 24D2.B2.Requirement 201: Treatment of neurodegenerative diseasesUnderstand how to manage antibodies in patients with neurodegenerative diseases from any 1 to 190 requirements.The pharmaceutical ingredients in claim 191, or the double antibodies in claim 192.